Observational analysis shows improved endo-histological outcomes in ulcerative colitis, suggesting mucosal restoration with filgotinib.
Filgotinib improved endo-histological outcomes in patients with UC, with a dose-dependent effect on transcription. Gene expression changes and enriched pathways suggest that achieving endoscopic and histological endpoints in patients receiving FIL was associated with the restoration of mucosal homeostasis.
No takes yet. Share an insight, caveat, or question.
Magro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: